Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Noxopharm Ltd V.NOX


Primary Symbol: NOXOF

Noxopharm Limited is a biotech company. It is engaged in discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to enhance messenger ribonucleic acid (mRNA) vaccines. It utilizes specialist in-house capabilities and partnerships with researchers to build a pipeline of new proprietary drugs based on two technology platforms: Chroma (oncology) and Sofra (inflammation, autoimmunity, and mRNA vaccine enhancement). Chroma is a technology platform focused on the development of multiple drug candidates, primarily for cancer treatment. The Sofra technology platform has a pipeline of proprietary drugs based on oligonucleotides, the building blocks of deoxyribonucleic acid (DNA), with a focus on mRNA vaccines and the treatment of autoimmune and inflammatory diseases. SOF-VAC has applications in the treatment of excessive inflammatory responses associated with specialized inflammatory receptors in the body known as Toll-like receptor 7.


OTCPK:NOXOF - Post by User

Post by nopooon Oct 28, 2012 10:54am
187 Views
Post# 20532244

Strpping Ratio and Things

Strpping Ratio and Things

Stripping a deposit of overburden, removal of the rock/dirt on top of the ore, is nothing more then an earth moving exercise.$2 a tonne seems very high, I would expect costs of less then $1 per tonne, maybe as low as .50. Time will tell.

 

Lets remember, excessive,imo, capping lost us 650,000 ozs of gold, Phase 2 was not counted and again imo Aurizon will do a phase 3 - analysts expect up to 3m ozs here. Aurizon has some problems with other projects and this is pretty much the best of their bunch, tell me what else do they have to keep production levels up, or increase them, for their shareholders?

 

Think about this -  If this does, as forecast, hit 3m ozs by next July's 3rd anniversary date,where in the world could you pick up M&I for $40 an oz? You just bought 1.5m ozs of gold, mostly in the M&I category, for $40 an oz ($30 for Inferred) while most Co's are paying well over $110 an oz, do you think you could afford to prestrip?

 

Take things a step further.....

 

and look at it another way - Aurizon (if the deposit is 3m ozs of gold), gets another 450,000 ozs for doing a Feasability study, and arranging financing for NioGold - basically Aurizon gets almost 2m ozs of gold - 1.5m + 450k = 1.95 ozs of gold - for $40.00 per oz and say $20m for the studies. Thats just $80m!

 

Other Co's - $100 an oz for M&I = $195m plus the cost of the studies.

 

For $80m - plus pre-stripping costs - Aurizon gets a 2m oz gold mine ready to finance for production, thats $3.4 billion worth of gold at spot of $1700, a 10% in-situ value of $340m - ask yourself - Is Aurizon going to walk?

 

ttfn

nopoo

 

 

<< Previous
Bullboard Posts
Next >>